NASDAQ:OVID - Ovid Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.81 -0.20 (-3.33 %) (As of 10/16/2018 04:48 AM ET)Previous Close$6.01Today's Range$5.60 - $5.9952-Week Range$5.20 - $12.44Volume141,700 shsAverage Volume78,850 shsMarket Capitalization$139.66 millionP/E Ratio-1.74Dividend YieldN/ABeta1.29 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate that is in Phase Ib/IIa trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the clinical setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York. Receive OVID News and Ratings via Email Sign-up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:OVID CUSIPN/A Webwww.ovidrx.com Phone646-661-7661 Debt Debt-to-Equity RatioN/A Current Ratio8.70 Quick Ratio8.70 Price-To-Earnings Trailing P/E Ratio-1.74 Forward P/E Ratio-2.57 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$3.39 per share Price / Book1.71 Profitability EPS (Most Recent Fiscal Year)($3.35) Net Income$-64,800,000.00 Net MarginsN/A Return on Equity-60.00% Return on Assets-55.57% Miscellaneous Employees43 Outstanding Shares24,630,000Market Cap$139.66 million Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions What is Ovid Therapeutics' stock symbol? Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID." How were Ovid Therapeutics' earnings last quarter? Ovid Therapeutics Inc (NASDAQ:OVID) posted its earnings results on Thursday, August, 9th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.60) by $0.07. View Ovid Therapeutics' Earnings History. When is Ovid Therapeutics' next earnings date? Ovid Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 8th 2018. View Earnings Estimates for Ovid Therapeutics. What price target have analysts set for OVID? 3 brokerages have issued 1-year price objectives for Ovid Therapeutics' shares. Their forecasts range from $20.00 to $27.00. On average, they anticipate Ovid Therapeutics' stock price to reach $23.50 in the next year. This suggests a possible upside of 304.5% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics. What is the consensus analysts' recommendation for Ovid Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics. Who are some of Ovid Therapeutics' key competitors? Some companies that are related to Ovid Therapeutics include TIGENIX/S (TIG), Adamas Pharmaceuticals (ADMS), Cytokinetics (CYTK), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), AC Immune (ACIU), Arbutus Biopharma (ABUS), MediciNova (MNOV), Odonate Therapeutics (ODT), Prothena (PRTA), Theratechnologies (THERF), Stemline Therapeutics (STML), OptiNose (OPTN), Achillion Pharmaceuticals (ACHN) and ZEALAND PHARMA/S (ZEAL). Who are Ovid Therapeutics' key executives? Ovid Therapeutics' management team includes the folowing people: Dr. Jeremy Max Levin, Chairman & CEO (Age 65)Dr. Matthew J. During, Founder, Pres, Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 61)Dr. Yaron Werber, Chief Bus. Officer, CFO & Treasurer (Age 46)Ms. Lora Pike, Sr. Director of Investor Relations & PRMs. Ana C. Ward Esq., M.S., M.B.A., Sr. VP, Gen. Counsel & Secretray (Age 50) When did Ovid Therapeutics IPO? (OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers. How do I buy shares of Ovid Therapeutics? Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ovid Therapeutics' stock price today? One share of OVID stock can currently be purchased for approximately $5.81. How big of a company is Ovid Therapeutics? Ovid Therapeutics has a market capitalization of $139.66 million. The company earns $-64,800,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Ovid Therapeutics employs 43 workers across the globe. What is Ovid Therapeutics' official website? The official website for Ovid Therapeutics is http://www.ovidrx.com. How can I contact Ovid Therapeutics? Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected] MarketBeat Community Rating for Ovid Therapeutics (NASDAQ OVID)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 183 (Vote Outperform)Underperform Votes: 147 (Vote Underperform)Total Votes: 330MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe OVID will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVID will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/16/2018 by MarketBeat.com StaffFeatured Article: How can investors find ex-dividend dates?